{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:45:46Z","timestamp":1785861946339,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,26]]},"DOI":"10.1097\/01.aids.0000233574.49220.de","type":"journal-article","created":{"date-parts":[[2006,6,20]],"date-time":"2006-06-20T05:00:53Z","timestamp":1150779653000},"page":"1407-1414","source":"Crossref","is-referenced-by-count":69,"title":["Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir"],"prefix":"10.1097","volume":"20","author":[{"given":"Josep M","family":"Llibre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J","family":"P\u00e9rez-El\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainel","family":"S\u00e1nchez-de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.amjcard.2004.11.004","article-title":"Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy","volume":"95","author":"Grover","year":"2005","journal-title":"Am J Cardiol"},{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 2","key":"R3-7-20210130","first-page":"S123","article-title":"HIV, HAART, and hyperlipemia: Balancing the effects","volume":"34","author":"Sherer","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-7-20210130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group","volume":"37","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1468-1293.2005.00269.x","article-title":"Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study","volume":"6","author":"Richter","year":"2005","journal-title":"HIV Med"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00129784-200404050-00004","article-title":"HIV-related cardiovascular disease and drug interactions","volume":"4","author":"Nanavati","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"issue":"Suppl 1","key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/00126334-200309011-00011","article-title":"Cardiovascular risk factors in HIV-infected patients","volume":"34","author":"Carr","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"R11-7-20210130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350400900507","article-title":"Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy","volume":"9","author":"Martinez","year":"2004","journal-title":"Antiviral Therapy"},{"key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1468-1293.2005.00309.x","article-title":"The role of diet, exercise and smoking in dyslipidemia in HIV-infected patients with lipodystrophy","volume":"6","author":"Shah","year":"2005","journal-title":"HIV Med"},{"key":"R13-7-20210130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"Fisac","year":"2005","journal-title":"AIDS"},{"key":"R15-7-20210130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"R16-7-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00042560-200201010-00003","article-title":"Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-7-20210130","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"R18-7-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"R19-7-20210130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-7-20210130","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/00002030-200007280-00016","article-title":"A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II)","volume":"14","author":"Eron","year":"2000","journal-title":"AIDS"},{"key":"R22-7-20210130","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00002030-200007280-00015","article-title":"A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination witrh indinavir in antiretroviral na\u00efve individuals with HIV infection: selection of thymidine analog regimen therapy (START I)","volume":"14","author":"Squires","year":"2000","journal-title":"AIDS"},{"key":"R23-7-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF v stavudine in combination therapy in antiretroviral naive patients","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R25-7-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.curtheres.2005.04.002","article-title":"Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: a prospective, observational study","volume":"66","author":"Palacios","year":"2005","journal-title":"Curr Ther Res"},{"key":"R26-7-20210130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jama.292.2.251","article-title":"Treatment for Adult HIV Infection. 2004 Recommendations of the International AIDS Society-USA Panel","volume":"292","author":"Yeni","year":"2004","journal-title":"JAMA"},{"key":"R27-7-20210130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1157\/13069520","article-title":"Spanish GESIDA\/Nacional AIDS Plan Recommendations for Antiretroviral Therapy in HIV-infected Adults (October 2004)","volume":"22","author":"Iribarren","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R28-7-20210130","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R29-7-20210130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.aids.0000166087.08822.bc","article-title":"Cardiovascular disease in HIV-positive patients","volume":"19","author":"Kamin","year":"2005","journal-title":"AIDS"},{"key":"R30-7-20210130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-7-20210130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"key":"R32-7-20210130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.aids.0000131343.53419.04","article-title":"Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results","volume":"18","author":"Domingo","year":"2004","journal-title":"AIDS"},{"key":"R33-7-20210130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00126334-200308010-00018","article-title":"Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens","volume":"33","author":"Lafeuillade","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-7-20210130","first-page":"4","article-title":"Infectious Disease Society of America, AIDS Clinical Trials Group. New guidelines for management of dyslipidemia from IDSA and the ACTG","volume":"16","author":"Bartlett","year":"2004","journal-title":"The Hopkins HIV Report"},{"key":"R35-7-20210130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. A randomized trial","volume":"139","author":"Squires","year":"2003","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"R36-7-20210130","first-page":"9","article-title":"Switching from a thymidine analogue to tenofovir (TDF) achieves similar resolution of lipoatrophy and better reduction in lipids than switching to abacavir (ABC). Results of the RAVE study, a UK multi-centre open-label randomised controlled trial: 033","volume":"6","author":"Cartledge","year":"2005","journal-title":"HIV Med"},{"key":"R37-7-20210130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0398-0499(04)96747-9","article-title":"Antiretroviral therapy and cardiovascular risk","volume":"29","author":"Vandhuick","year":"2004","journal-title":"J Maladies Vasculaires"},{"key":"R38-7-20210130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"R39-7-20210130","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","article-title":"Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile","volume":"15","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"R40-7-20210130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.qai.0000143037.70120.fc","article-title":"An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine","volume":"38","author":"Manfredi","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-7-20210130","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1074\/jbc.M312875200","article-title":"In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes","volume":"279","author":"Hadri","year":"2004","journal-title":"J Biol Chem"},{"key":"R42-7-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001756-200607170-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:45:28Z","timestamp":1785858328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200606260-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,26]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000233574.49220.de","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6,26]]}}}